Skull Shaver’s Early Bird Sale
Trying to take advantage of this sale may not be as smooth as advertised.
Global Institute of Stem Cell Therapy and Research
In May 2020, a class-action lawsuit was filed against Global Institute of Stem Cell Therapy and Research for allegedly:
- Misleadingly representing that its stem cell therapy treatment can treat multiple diseases – including sickle cell anemia, leukemia, lymphoma, and thalassemia – when, according to the complaint, the treatment does not treat such diseases and is not approved by the FDA;
- Failing to disclose the risks associated with the treatment;
- Making false statements about one of the co-founder’s education, academic appointments, and clinical experience; and
- Falsely claiming that the defendants are affiliated with and have stem cell clinics set up at reputable medical institutions when, according to plaintiffs, they are not affiliated with and do not have clinics at the institutions.
Plaintiffs also claim that the defendants are not licensed to perform stem cell treatments in the United States. (Mendez et al v. Global Institute of Stem Cell Therapy and Research USA et al, Case No. 20-cv-915, S.D. Cal.)
The Latest
Roblox Bid for Ad Riches Collides With Wary Sponsors, Developers
Cecilia D’Anastasio, Bloomberg
UIC Aspire Grant
TINA.org digs into school’s debt-free claims.
TINA.org Joins Consumer Advocates to Keep FTC Bipartisan
Why agency independence is in the best interests of consumers.
Tracksmith’s ‘100 Mile Guarantee’
What exactly does this running brand mean by “your return is on us”?